Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28946743 | 1.00 | CASP3 (0.49) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL30896049 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL14019298 | 0.89 | POLB (0.51) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL31546599 | 0.89 | POLB (0.51) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1486287 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL119497 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL118209 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1486214 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1564185 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL6038102 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521358-A | Preparation method of destruxins B | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | claimed |
| CN-115521358-A | Preparation method of destruxins B | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | disclosed |
| CN-115521358-A | Preparation method of destruxins B | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | disclosed |
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | CASP3 619/4885KMT2A 112/4885PIN1 3801/4885 |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | CASP3 4586/4885KMT2A 171/4885PIN1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.